Erika Chelales
Concepts (56)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Cellulose | 3 | 2021 | 57 | 0.990 |
Why?
|
| Ethanol | 4 | 2021 | 548 | 0.880 |
Why?
|
| Liver | 1 | 2021 | 1681 | 0.450 |
Why?
|
| Catheter Ablation | 3 | 2021 | 291 | 0.440 |
Why?
|
| Liver Neoplasms | 2 | 2021 | 516 | 0.270 |
Why?
|
| Models, Animal | 2 | 2021 | 348 | 0.210 |
Why?
|
| Acidosis | 1 | 2022 | 87 | 0.190 |
Why?
|
| Nephelometry and Turbidimetry | 1 | 2021 | 16 | 0.190 |
Why?
|
| Uterine Cervical Dysplasia | 1 | 2021 | 39 | 0.190 |
Why?
|
| Rats, Inbred F344 | 1 | 2021 | 241 | 0.190 |
Why?
|
| Necrosis | 1 | 2021 | 210 | 0.180 |
Why?
|
| Central Nervous System Depressants | 1 | 2021 | 82 | 0.180 |
Why?
|
| Triple Negative Breast Neoplasms | 1 | 2022 | 157 | 0.170 |
Why?
|
| Thrombelastography | 1 | 2021 | 179 | 0.170 |
Why?
|
| Accommodation, Ocular | 1 | 2019 | 10 | 0.170 |
Why?
|
| Blood Coagulation | 1 | 2021 | 221 | 0.170 |
Why?
|
| Breast Neoplasms | 2 | 2021 | 1865 | 0.160 |
Why?
|
| Drug Labeling | 1 | 2019 | 42 | 0.160 |
Why?
|
| Presbyopia | 1 | 2019 | 11 | 0.160 |
Why?
|
| Mass Media | 1 | 2019 | 37 | 0.160 |
Why?
|
| Carcinoma, Hepatocellular | 1 | 2019 | 218 | 0.150 |
Why?
|
| Vision Disorders | 1 | 2019 | 130 | 0.150 |
Why?
|
| Reading | 1 | 2019 | 149 | 0.150 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 2020 | 856 | 0.120 |
Why?
|
| Rats | 1 | 2021 | 4973 | 0.110 |
Why?
|
| Animals | 5 | 2022 | 31867 | 0.090 |
Why?
|
| Mice, Inbred BALB C | 2 | 2022 | 1153 | 0.080 |
Why?
|
| Swine | 2 | 2021 | 704 | 0.080 |
Why?
|
| Female | 4 | 2021 | 59617 | 0.050 |
Why?
|
| Cyclophosphamide | 1 | 2022 | 217 | 0.050 |
Why?
|
| Fluorescein | 1 | 2021 | 26 | 0.050 |
Why?
|
| Needles | 1 | 2021 | 51 | 0.050 |
Why?
|
| Injections | 1 | 2021 | 159 | 0.050 |
Why?
|
| Drug Monitoring | 1 | 2021 | 184 | 0.040 |
Why?
|
| T-Lymphocytes, Regulatory | 1 | 2022 | 340 | 0.040 |
Why?
|
| Tumor Microenvironment | 1 | 2022 | 431 | 0.040 |
Why?
|
| Pupil | 1 | 2019 | 13 | 0.040 |
Why?
|
| Mice, Nude | 1 | 2021 | 631 | 0.040 |
Why?
|
| Tumor Cells, Cultured | 1 | 2021 | 851 | 0.040 |
Why?
|
| Male | 2 | 2021 | 55735 | 0.040 |
Why?
|
| Xenograft Model Antitumor Assays | 1 | 2021 | 697 | 0.040 |
Why?
|
| Feasibility Studies | 1 | 2021 | 746 | 0.040 |
Why?
|
| Visual Acuity | 1 | 2019 | 274 | 0.040 |
Why?
|
| Neoplasm Staging | 1 | 2020 | 1169 | 0.030 |
Why?
|
| Anticoagulants | 1 | 2021 | 546 | 0.030 |
Why?
|
| Cell Line, Tumor | 1 | 2022 | 2715 | 0.030 |
Why?
|
| Mice | 2 | 2022 | 14927 | 0.030 |
Why?
|
| Reproducibility of Results | 1 | 2021 | 2799 | 0.030 |
Why?
|
| Cell Proliferation | 1 | 2021 | 2191 | 0.030 |
Why?
|
| Mice, Inbred C57BL | 1 | 2022 | 4718 | 0.030 |
Why?
|
| Humans | 5 | 2022 | 115047 | 0.030 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2021 | 2341 | 0.020 |
Why?
|
| Apoptosis | 1 | 2021 | 2366 | 0.020 |
Why?
|
| Risk Assessment | 1 | 2020 | 2976 | 0.020 |
Why?
|
| Middle Aged | 1 | 2019 | 26830 | 0.010 |
Why?
|
| Adult | 1 | 2019 | 30658 | 0.010 |
Why?
|